Form 4: Tandem Diabetes CTO Reports RSU Vesting & Tax Withholding
Insider Transaction Report
Tandem Diabetes Care's Chief Technology Officer, Rick Carpenter, reported the vesting of 406 restricted stock units and subsequent withholding of 207 shares for tax obligations.
Summary
- Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care Inc. (TNDM), reported transactions related to his beneficial ownership.
- On December 15, 2025, 406 restricted stock units (RSUs) vested, resulting in the acquisition of 406 shares of common stock at a price of $0.
- Concurrently, 207 shares were disposed of by the company to satisfy tax withholding requirements related to the RSU vesting, at a price of $22.11 per share.
- Following these transactions, Carpenter beneficially owns 24,252 shares of Tandem Diabetes Care common stock.
- The RSU award was granted on December 15, 2021, under the Tandem Diabetes Care Inc. 2013 Stock Incentive Plan.
Sentiment
Score: 5
Explanation: The filing reports a routine insider transaction involving the vesting of restricted stock units and subsequent tax withholding, which is a standard part of executive compensation and does not indicate any significant positive or negative operational or financial news.
Positives
- Vesting of restricted stock units indicates the execution of a long-term incentive plan for a key executive.
- The transaction is a routine part of executive compensation, aligning management interests with shareholder value over time.
Negatives
- A portion of the vested shares (207 shares) was withheld by the company to cover tax obligations, reducing the net shares received by the executive, which is a standard practice.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Compensation Plan | The Restricted Stock Units were awarded pursuant to the Tandem Diabetes Care Inc. 2013 Stock Incentive Plan, as amended, which governs executive equity compensation. | 12/15/2021 (Award Date) | Reinforces the company's established equity compensation framework for aligning executive incentives with long-term company performance. |
Stakeholder Impact
- Shareholders: The transaction is a routine part of executive compensation and does not materially impact the company's overall share structure or financial health.
- Employees: Reflects the standard operation of the company's equity incentive plans for key personnel.
Next Steps
- Remaining shares of the RSU award will vest in twelve equal quarterly installments following December 15, 2022.
Key Dates
| Date | Description |
|---|---|
| 12/15/2021 | Date Restricted Stock Unit (RSU) award was granted. |
| 12/15/2022 | First vesting date for 25% of the total RSU shares. |
| 12/15/2025 | Transaction date for RSU vesting and tax withholding. |
| 12/17/2025 | Signature date of the reporting person's attorney-in-fact. |
Recommendation
holdThis Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and subsequent tax withholding for a key executive. Such transactions are pre-scheduled and do not reflect new operational performance, strategic shifts, or material changes in the company's financial outlook. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based on existing fundamentals.
Keywords
TNDM, Tandem Diabetes Care, Form 4, insider trading, stock transactions, RSU, restricted stock units, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.